Correction to: Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations

被引：0
|
作者：
George G. Zhanel
Courtney K. Lawrence
Heather Adam
Frank Schweizer
Sheryl Zelenitsky
Michael Zhanel
Philippe R. S. Lagacé-Wiens
Andrew Walkty
Andrew Denisuik
Alyssa Golden
Alfred S. Gin
Daryl J. Hoban
Joseph P. Lynch
James A. Karlowsky
机构：
[1] University of Manitoba,Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine
[2] University of Manitoba,College of Pharmacy
[3] University of Manitoba,Department of Chemistry, Faculty of Science
[4] Winnipeg Health Sciences Centre,Department of Medicine
[5] Winnipeg Health Sciences Centre,Department of Pharmacy
[6] Diagnostic Services Manitoba,Division of Pulmonary, Critical Care, Allergy and Clinical Immunology
[7] The David Geffen School of Medicine at UCLA,undefined
来源：
Drugs | 2018年 / 78卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Section heading 5.2, which currently reads 5.2 Meropenem–Relebactam.
引用
收藏
页码：787 / 787
相关论文
共 50 条
  • [21] Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination
    Novelli, Andrea
    Del Giacomo, Paola
    Rossolini, Gian Maria
    Tumbarello, Mario
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (07) : 643 - 655
  • [22] In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
    Bonnin, Remy A.
    Bernabeu, Sandrine
    Emeraud, Cecile
    Naas, Thierry
    Girlich, Delphine
    Jousset, Agnes B.
    Dortet, Laurent
    ANTIBIOTICS-BASEL, 2023, 12 (01):
  • [23] The in vitro effecteffect of new combinations of carbapenem-ßlactamase inhibitors for MycobacteriumabscessusMycobacterium abscessus
    Froberg, Gabrielle
    Ahmed, Ayan
    Chryssanthou, Erja
    Davies Forsman, Lina
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (10)
  • [24] First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
    Laffont-Lozes, Paul
    Naciri, Tayma
    Pantel, Alix
    Martin, Aurelie
    Pruvot-Occean, Anne-Sophie
    Haignere, Vincent
    Loubet, Paul
    Sotto, Albert
    Larcher, Romaric
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
    Rizk, Matthew L.
    Rhee, Elizabeth G.
    Jumes, Patricia A.
    Gotfried, Mark H.
    Zhao, Tian
    Mangin, Eric
    Bi, Sheng
    Chavez-Eng, Cynthia M.
    Zhang, Zufei
    Butterton, Joan R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (03)
  • [26] In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex
    Mendez-Sotelo, Braulio Josue
    Delgado-Beltran, Monica
    Hernandez-Duran, Melissa
    Colin-Castro, Claudia Adriana
    Esquivel-Bautista, Jose
    Ortega-Oliva, Sandra Angelica
    Ortiz-Alvarez, Jossue
    Garcia-Contreras, Rodolfo
    Franco-Cendejas, Rafael
    Lopez Jacome, Luis Esau
    PLOS ONE, 2024, 19 (04):
  • [27] Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
    Duda-Madej, Anna
    Viscardi, Szymon
    Topola, Ewa
    ANTIBIOTICS-BASEL, 2023, 12 (11):
  • [28] Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa
    Sophonsri, Anthony
    Kalu, Michelle
    Wong-Beringer, Annie
    ANTIBIOTICS-BASEL, 2024, 13 (05):
  • [29] Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to TargetKlebsiella pneumoniaeCarbapenemase-Producing Enterobacterales
    Hayden, Dillon A.
    White, Bryan P.
    Bennett, Kiya K.
    JOURNAL OF PHARMACY TECHNOLOGY, 2020, 36 (05) : 202 - 210
  • [30] Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
    Gaibani, Paolo
    Giani, Tommaso
    Bovo, Federica
    Lombardo, Donatella
    Amadesi, Stefano
    Lazzarotto, Tiziana
    Coppi, Marco
    Rossolini, Gian Maria
    Ambretti, Simone
    ANTIBIOTICS-BASEL, 2022, 11 (05):
12345